Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia - Wikidata - awgldk - TriplyDB

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q36834079

about

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin.Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.The role of Pax5 in leukemia: diagnosis and prognosis significance.The double-edged sword: Neurotoxicity of chemotherapy.Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity The Gyrolab™ immunoassay system: a platform for automated bioanalysis and rapid sample turnaround.A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

P2860

Q26775363-7C20F92E-35A6-42AE-BBE0-C8C5579EE986 Q26996159-418809F1-E7B7-42C7-B86B-F49C16964FB3 Q27316983-B04CC03A-39E5-4C93-B8A4-9B3959605E32 Q35119802-58A1DABF-2357-47A9-AAA4-0D04B23EBA2D Q35799427-671E5AF5-A4B2-4753-A111-A625DB6BF0EC Q37621354-8CD20290-044D-4795-8742-4877148F5A07 Q37708824-B4D1B6B4-5419-4790-A15A-EDD0BB7058C7 Q38271843-7370AA45-D45A-4913-AF8F-C3F4977184FE Q38274890-1361C944-B605-45B5-A4F5-EDEE433AAD13 Q38400420-B7E21E34-E195-41E6-99A6-5BBA47C1315B Q38707896-2AEC00E3-F950-4862-A447-79B268F40A14 Q38759431-93D96104-9354-457F-A059-C52337AD1F83 Q41048538-5B4269CF-F0F5-479E-A87D-D58DCD15545B Q42601428-9EC1B534-1C07-4879-88E0-C0393BC065A7 Q42810456-8BEF200F-64ED-4FA2-B7D0-04A019B331DD Q43830676-7691C2A5-AE45-449A-8855-05ADD4FA0869 Q49221285-0E567717-801C-4AEC-8834-29E03311F9DF Q53758334-F7680ABF-A2F7-4A05-AF18-10B26268FA2B Q56355417-3C6F3672-5EDC-41E9-BE4B-942B39CA5340

P2860

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q36834079

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Clinical and pharmacologic asp ...... l acute lymphoblastic leukemia

@en

type

label

Clinical and pharmacologic asp ...... l acute lymphoblastic leukemia

@en

prefLabel

Clinical and pharmacologic asp ...... l acute lymphoblastic leukemia

@en

P1433

Q36834079-18F3523E-3919-4F7B-9553-09BA0E4EB4BF

P1476

Q36834079-5BD5EDDC-035A-430C-BCE7-32BE7EB7B23C

P2093

Q36834079-18420E44-F49E-4916-B0D9-C557F0FDA73E

Q36834079-F4BBEE72-A69B-4F66-B984-82CA8BCEDE10

P2860

Q36834079-15975175-701B-46AB-AA7F-305B932CBF70

Q36834079-26CE2172-1A7D-4C73-B1B5-0A0FD21AB728

Q36834079-368D3EAB-1568-4F59-A9F8-92AB4F484A7A

Q36834079-3ADBBF01-D24C-4554-8AEF-AF14A2A3E4F8

Q36834079-3E968C13-F09F-4E24-B410-3EFC40D0BF92

Q36834079-43C300A5-E87F-4518-B51E-6120C548096B

Q36834079-5DC73E21-49E1-4C4F-8E51-BFEDDFA57154

Q36834079-66706438-CD28-4D2C-8A13-C2E02DDF11F2

Q36834079-71CA7C91-483D-4469-AE16-96B39A21DB69

Q36834079-742E54ED-B554-4FF6-81A2-B9B82AE52EB8

P304

Q36834079-B9B6CC8D-2004-4496-979A-49E6D7991B44

P31

Q36834079-ABE03203-F780-44CC-9957-B5503EE42295

P356

Q36834079-92E322D5-9826-4F5B-9443-680D8B87C6B4

P407

Q36834079-7046A187-5D37-4FD9-A5FB-09D576F3FF89

P433

Q36834079-16E03C97-3599-4D53-823B-CCCF1CCE909B

P478

Q36834079-817BDE76-D3CE-4F15-941E-03FA476D9F29

P50

Q36834079-4D196463-7B11-4084-88CE-83331ECCE556

P577

Q36834079-D410C315-4B60-475B-85E8-994EBDB5EA7C

P698

Q36834079-F3B70E19-5F15-4E9E-AEF7-FD875ED787DE

P932

Q36834079-A089890D-6D2E-4E3E-A578-001C15787C70

P356

P1433

Clinical Pharmacology: Advances and Applications

P1476

Clinical and pharmacologic asp ...... l acute lymphoblastic leukemia

@en

P2093

Anjali S Advani

http://www.w3.org/2001/XMLSchema#string

Candice M Wenzell

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily

Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain

The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP

CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail

An antibody-deficiency syndrome due to mutations in the CD19 gene

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.

Cancer therapy with bispecific antibodies: Clinical experience.

P304

5-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CPAA.S42689

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23671399

http://www.w3.org/2001/XMLSchema#string

P932

3650887

http://www.w3.org/2001/XMLSchema#string